The Drugs Don't Work

And everyone at the AAN Annual Meeting knows it

A friend of mine just got back from the AAN (American Academy of Neurology) Annual meeting. If you’ve never been, this is where the neurologists go. The people running the trials, prescribing the drugs, shaping what becomes the standard of care. It’s not fringe. It’s the center.

And he said something that stuck with me.

He said, “This was the talk of the town.”

Not a breakthrough. Not a new molecule.

A realization.

Quiet, but spreading.

The drugs don’t work.

What he was referring to was a new analysis from the Cochrane Collaboration. They looked across 17 trials, more than 20,000 patients, and came to a conclusion that, if we’re honest,many people have felt for a while but haven’t wanted to say out loud.

Anti-amyloid drugs show no clinically meaningful benefit.

Not that they do nothing. They do exactly what they are designed to do. They remove amyloid plaques from the brain. You can see it on a scan. You can measure it.

But when you step back and ask the only question that really matters (does the patient actually get better?) the answer is, at best, not in a way that changes their life.

That’s a very different standard.

And from what I heard, this wasn’t just another paper. This was one of those moments where a field starts to shift. Not publicly, not all at once. But in the conversations in hallways, over coffee, between sessions.

When something becomes “the talk of the town” at a meeting like that, it means the people closest to the problem know something is off.

For decades, we’ve told a simple story about Alzheimer’s disease.

It’s about amyloid. Remove the amyloid, and you slow the disease.

It’s clean. It’s elegant. It’s fundable.

It’s also incomplete.

Because if that story were true in a clinically meaningful way, we wouldn’t be here. We wouldn’t have spent billions of dollars and decades of effort to arrive at marginal effects that barely move the needle for patients and families dealing with real decline.

The Cochrane review doesn’t just critique a set of drugs. It quietly dismantles the idea that a single-pathway solution is going to solve a multi-system problem.

And that creates a vacuum.

Because once you accept that the dominant approach isn’t delivering, the next question comes quickly:

So what does work?

If you zoom out from neurology conferences and look at what’s actually happening in clinics that are willing to try something different, a pattern starts to emerge.

The patients who stabilize, or even improve, are not the ones getting a single intervention.

They’re the ones where someone has taken the time to understand the full picture.

Metabolism.
Inflammation.
Sleep.
Toxins.
Hormones.
Nutrient status.
Gut health.
Stress.
Connection.

Not as a checklist. As a system.

For years, this has been easy to dismiss. It’s been called “lifestyle,” which makes it sound optional. Or “adjunctive,” which makes it sound secondary.

But if you’ve sat with enough of these cases, you start to see something different. You start to see that these are not side issues. They are the terrain in which the disease either progresses or recedes.

And once you see that, it’s hard to unsee it.

At the end of last year, something happened that, in my view, hasn’t fully landed yet.

A randomized controlled trial, still the gold standard in medicine, looked at a precision, multi-factorial approach to Alzheimer’s disease.

Six clinical sites. Experienced clinicians. Real patients. Real complexity.

And the results didn’t just show statistical significance. They showed changes that clinicians would recognize. Patients improving in ways that matter. Cognition, function, trajectory.

You don’t see that often in this field.

Certainly not in a way that stands in such stark contrast to what we’ve come to expect from drug trials.

But what’s most exciting to me isn’t just the trial.

It’s what’s happening now.

Last week in Colorado, Dr. Jessica Knape shared something that felt like the next chapter.

She’s been using TruNeura as the operating system inside her clinic. Not just to organize care.
But to deliver this model consistently.

And because her patients are inside that system, because the data is structured, because the journey is tracked, she’s now able to see something clearly:

Her patients are getting better.

Not anecdotally.

Measurably.

MOCA scores are going up. Cognitive function improving. Patients moving in the right direction.

The same signal we saw in the randomized controlled trial…

Now showing up in her real-world practice.

That’s the shift.

Because one trial is interesting.

But replication is everything.

And what Dr. Knape is demonstrating is that this isn’t just something that can happen in a tightly controlled study.

It’s something that can happen in a clinic.

With real patients. With real constraints. In the flow of everyday care.

This is how new standards are born.

Not from a single paper.

But from a method that can be learned, implemented, and repeated.

A proven methodology.

Applied consistently.

Across practitioners.

Across clinics.

Across networks.

Across time.

If the last decade was about asking, “Is it possible to improve cognitive decline?”

The next decade is about answering a different question:

Can we scale it?

Can we take what worked in the randomized controlled trial…
What’s now working in clinics like Dr. Knape’s…

And make it available to thousands of practitioners and millions of patients?

That’s the work now.

Because once you accept that the drugs don’t work in a meaningful way, you don’t just need a better option.

You need a system that makes that better option deliverable.

Trackable. Repeatable. Scalable.

“The drugs don’t work” is what people are starting to say out loud.

What comes next is quieter, but more important:

This does.

And now, for the first time, we’re not just seeing it in trials.

We’re seeing it in practice.

And that’s how a movement becomes a standard.